Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and results

Arthritis and Rheumatism

Volumn 64, Issue 1, 2012, Pages 21-32

  Solomon, D H ^a   Mercer, E ^a   Kavanaugh, A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Thornton Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; DATA BASE; HEMATOLOGIC MALIGNANCY; HUMAN; INFORMATION PROCESSING; LEUKEMIA; LUNG CANCER; LYMPHOMA; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANCER; SOLID TUMOR; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; NEOPLASMS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855275896     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30653     Document Type: Review

References (41)

1. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2009; 69 SUPPL. 1: i2-29.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84. (Pubitemid 351847559)
3. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
4. Lin WW, Karin M,. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-83. (Pubitemid 46718402)
5. Perkins ND,. NF-κB: tumor promoter or suppressor? Trends Cell Biol 2004; 14: 64-9.
6. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12: R5.
7. Thorley-Lawson DA,. EBV the prototypical human tumor virus: just how bad is it? J Allergy Clin Immunol 2005; 116: 251-61; quiz 262. (Pubitemid 41096526)
8. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48: 963-70. (Pubitemid 36418238)
9. Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 2010; 69: 654-9.
10. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D,. Cancer risk with tumor necrosis factor α (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2010; 20: 119-30.
11. Leombruno JP, Einarson TR, Keystone EC,. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45.
12. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
13. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ,. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68: 1177-83.
14. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
15. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329: 15-9. (Pubitemid 38869995)
16. Smitten AL, Simon TA, Hochberg MC, Suissa S,. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R45.
17. Cochrane Collaboration open learning material for reviewers. Version 1.1, November 2002.
18. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-53.
19. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20. (Pubitemid 41623850)
20. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180-9.
21. Chakravarty EF, Michaud K, Wolfe F,. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5. (Pubitemid 41587856)
22. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703. (Pubitemid 40559295)
23. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2757-64. (Pubitemid 44497754)
24. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95. (Pubitemid 47502734)
25. Wolfe F, Michaud K,. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9. (Pubitemid 46764070)
26. Bernatsky S, Clarke A, Suissa S,. Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung Cancer 2008; 59: 266-9. (Pubitemid 351173401)
27. Bernatsky S, Clarke AE, Suissa S,. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168: 378-81. (Pubitemid 351347129)
28. Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L,. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008; 37: 388-97. (Pubitemid 351734521)
29. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6. (Pubitemid 41623851)
30. Franklin J, Lunt M, Bunn D, Symmons D, Silman A,. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006; 65: 617-22.
31. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J,. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909-15. (Pubitemid 35332027)
32. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010; 69: 400-8.
33. Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010; 9: 175-80.
34. Wolfe F, Michaud K,. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51. (Pubitemid 38725085)
35. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP,. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62: 755-63.
36. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20. (Pubitemid 37323253)
37. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010; 69: 1596-602.
38. Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45 (10 SUPPL. 2): S131-42.
39. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ,. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005; 161: 891-8. (Pubitemid 40577844)
40. Dixon W, Silman A,. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther 2006; 8: 111.
41. Anderson GM, Nakada MT, DeWitte M,. Tumor necrosis factor-α in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 314-20. (Pubitemid 38987055)